

Christoph B. Olivier

Personal Data

Name	Christoph Benedikt Olivier
Date of birth	May 7 th , 1982 (Villingen-Schwenningen, Germany)
Name of institution	Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen, Faculty of Medicine, University of Freiburg
Address	Hugstetter Str. 55 79106 Freiburg, Germany
Email	Christoph.Olivier@uniklinik-freiburg.de
Web	www.antithrombotic.org; linkedin: christoph-b-olivier-7647b980



Curriculum Vitae

Education

2020	Postdoctoral Thesis (Habilitation); Faculty of Medicine, University of Freiburg.
2007 – 2010	Doctoral Thesis; Faculty of Medicine, University of Freiburg.
2010	Graduation (Medical Doctor) and license (Approbation); Faculty of Medicine, University of Freiburg; Landesärztekammer Baden-Württemberg.
2002 – 2010	Medical School, University of Freiburg.

Board Certifications

2021	Internal Medicine and Cardiology (Landesärztekammer Baden-Württemberg).
2016	Internal Medicine (Landesärztekammer Baden-Württemberg).

Current Positions

Since 2024	Director, Antithrombotic Research Group, University Heart Center Freiburg Bad Krozingen.
Since 2024	Associate Professor, Faculty of Medicine, University of Freiburg.
Since 04/2024	Head of Clinical Research, Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen (Chair: Prof. Dr. Westermann).
Since 07/2023	Director, Cardiovascular Clinical Research Center (CCRC), Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen.
Since 10/2020	Attending Physician, Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen.

Previous Positions

2020 – 2024	Assistant Professor, Faculty of Medicine, University of Freiburg.
-------------	---

Christoph B. Olivier

2016 – 2020	Cardiovascular fellow (2019 – 2020: chief fellow) and clinician scientist, Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen.
2016 – 2019	Postdoctoral research fellow; Stanford Center for Clinical Research (Prof. Dr. Mahaffey) and Center for Digital Health (Prof. Dr. Turakhia), Department of Medicine (Chair: Prof. Dr. Harrington), Stanford University School of Medicine, Stanford, USA.
2010 – 2016	Resident and clinician scientist, Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen.

Research Grants and Awards

Research Support, public, non-profit, or intramural

2025 – 2027	BMBF for the Project: GENder Knowledge Gap in contemporary CARDiovascular trials (GEN-CARD).
2022 – 2026	Acribis “Advancing Cardiovascular Risk Identification with Structured Clinical Documentation and Biosignal Derived Phenotypes Synthesis”.
2022 – 2024	Else Kröner-Fresenius Stiftung, “Hemostatic Profiling to Enable Personalized Antithrombotic Therapy in Patients after Transcatheter Aortic Valve Replacement”.
2022 – 2023	Deutsche Herzstiftung, “Accuracy of estimation of effect sizes and event rates”.
2021 – 2022	Fellow “Advanced Clinician Scientist”, Berta-Ottenstein-Programm, Faculty of Medicine, University of Freiburg.
2019 – 2021	“Förderprogramm Klinische Studien”, Faculty of Medicine, University of Freiburg
2016 – 2019	Deutsche Forschungsgemeinschaft (DFG) Research Grant OL 371/2-1 – research fellowship at Stanford University School of Medicine, Stanford, USA; The design and conduct of clinical trials for antithrombotic therapy in cardiac patients.
2011 – 2013	DFG Research Grant OL 371/1-1; The influence of dabigatran and rivaoraxaban on platelet function.

Research Support, industry

2021 – 2023	Is High Platelet Reactivity as Assessed by Thromboelastography associated with ischemic events in Patients with Atrial Fibrillation after coronary stenting?; Haemonetics IIS grant.
2020 – 2023	Risk stratification for subclinical leaflet thrombosis post Transcatheter Aortic valve implantation using Thromboelastography; Haemonetics IIS grant.

Personal Awards

2019	Young Cardiologist grant; Scientific Sessions 2019, European Society of Cardiology.
------	---

Christoph B. Olivier

2018	Young Investigator Award – Coronary Heart Disease; Annual Meeting of the German Cardiac Society 2018.
2017	Stanford Cardiovascular Institute grant, Stanford University.
2012	Young Cardiologist grant; Scientific Sessions 2012, European Society of Cardiology.
2010	DFG grant fellowship “Nachwuchsakademie Klinische Studien”.
2008	Grant “Prof. Dr. Dr. Freifrau von Kleist Stiftung” for participation at the Scientific Session 2008 of the American Heart Association.

Awards and Grants to Mentees

2025	First Price DGK Young Investigator Award – Koronare Herzerkrankungen to Dr. Celina Blank for the Project: Inzidenz, antothrombotische Strategien und Verlauf linksventrikulärer “Thromben nach Myokardinfarkt –eine retrospective monozentrische Analyse”.
2025	2025 Deutsche Gesellschaft für Kardiologie “Abstractpreis Kardiovaskuläre Versorgungsforschung” to Dr. Mariya Maslarska for her abstract “Death and cardiovascular death in major cardiovascular trials: Meta-analysis of major cardiovascular” trials published between 2010 and 2019”.
2024	Deutsche Forschungsgemeinschaft „Benjamin Walter Stipendium“ to Dr. Diona Gjermeni at the Stanford Center for Clinical Research.
2023	Deutsche Herzstiftung „Kaltenbach-Doktorandenstipendium“ to Dr. Annabel Hölzle for her doctoral thesis.
2022	Otto-Hess-Grant by the German Cardiac Society to Dr. Sofia Szabó for her doctoral thesis.
2022	Best Abstract to Lasse Struss; Annual Meeting of the German Cardiac Society 2022.

Publication list, by categories

Original, first-authored

1. **Olivier CB**, Struß L, Suennen N, Kaier K, Heger L, Westermann D, Meerpohl JJ., Mahaffey KW. Accuracy of Event Rate and Effect Size Estimation in Major Cardiovascular Trials. JAMA Netw Open. 2024 Apr 1;7(4):e248818. doi: 10.1001/jamanetworkopen.2024.8818. (JCR 2023: IF 24)
2. **Olivier CB**, Middleton SK, Purington N, Shashidhar S, Hereford J, Mahaffey KW, Turakhia MP. Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation. Cardiovascular Digital Health Journal 2021;2:101–108 (JCR 2023: IF 2.6)
3. **Olivier CB**, Sundaram V, Chertow G, Shashidhar S, McDonnell K, Ding V, Desai M, Mahaffey KW, Mell M. A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. J Vasc Access. 2020 Jul;21(4):467-474. (JCR 2018: IF 1.4)
4. **Olivier CB**, Fan J, Askari M, Mahaffey KW, Heidenreich PA, Perino AC, Leef GC, Ho PM, Harrington RA, Turakhia MP; Site Variation and Outcomes for Antithrombotic Therapy in AF Patients after PCI: Findings from the Veterans Health Administration. Circ Cardiovasc Interv. 2019 Aug;12(8):e007604. (JCR 2018: IF 6.1)

5. **Olivier CB**, Bhatt DL, Leonardi S, Stone GW, Gibson CM, Steg PG, Hamm CW, Wilson MD, Mangum S, Price MJ, Prats J, White HD, Lopes RD, Harrington RA, Mahaffey KW; Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX. *Circ Cardiovasc Interv.* 2019 Jul;12(7):e007342. (JCR 2018: IF 6.1)
6. **Olivier CB**, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW. Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. *JAMA Cardiol.* 2019 Jan 1;4(1):7-15. (JCR 2019: IF 14.7)
7. **Olivier CB**, Sundaram V, Bhatt DL, Leonardi S, Lopes RD, Ding VY, Yang L, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, White HD, Desai M, Lynch DR., Harrington RA, Mahaffey KW. Definitions of Peri-Procedural Myocardial Infarction and the Association with One-Year Mortality: Insights from CHAMPION Trials. *Int J Cardiol.* 2018 Nov 1;270:96-101 (JCR 2016: IF 6.2)
8. **Olivier CB**, Weik P, Meyer M, Weber S, Diehl P, Bode C, Moser M, Zhou Q. Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. *J Thromb Thrombolysis.* 2016 Aug;42(2):161-6 (JCR 2023: IF 2.3)
9. **Olivier CB**, Meyer M, Bauer H, Schnabel K, Weik P, Zhou Q, Bode C, Moser M, Diehl P. The ratio of ADP- to TRAP-induced platelet aggregation quantifies P2Y12-dependent platelet inhibition independently of the platelet count. *PLoS One.* 2016 Feb 17;11(2):e0149053. (JCR 2014: IF 3.2)
10. **Olivier CB**, Schnabel K, Weber S, Zhou Q, Bode C, Moser M, Diehl P. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on bodyweight in contrast to clopidogrel. *J Thromb Thrombolysis.* 2016 Jul;42(1):84-9. (JCR 2023: IF 2.3)
11. **Olivier CB**, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. *Thromb Res.* 2016 Feb;138:63-8. (JCR 2014: IF 2.4)
12. **Olivier CB**, Schnabel K, Brandt C, Weik P, Olschewski M, Zhou Q, Bode C, Diehl P, Moser M. A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. *Clin Res Cardiol.* 2014 Dec;103(12):968-75. (JCR 2013: IF 4.2)
13. **Olivier CB**, Diehl P, Schnabel K, Weik P, Zhou Q; Bode C, Moser M. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. *Thromb Haemost.* 2014 Feb;111(2):266-72. (JCR 2012: IF 6.1)

Original, last-authored

1. Gjermani, D., Anfang, V., Szabó, S., Vetter, H., Venhoff, A. C., Leggewie, S., Hesselbarth, D., Trenk, D., Buechse, M., Westermann, D., & **Olivier, CB.** (2024). D-dimer and fibrinogen indicate ischemic risk in patients with atrial fibrillation after percutaneous coronary intervention. *Thrombosis Journal*, 22(1), 42. doi: <https://doi.org/10.1186/s12959-024-00610-x> (JCR 2022: IF 3.1)
2. Gjermani D., Anfang V., Vetter H., Szabó S., Hesselbarth D., Gauchel N., Siegel PM., Kaier K., Kille A., Franke A., Leggewie S., Trenk D., Duerschmied D., Bode C., Westermann D., & **Olivier CB.** (2024). Low on-clopidogrel ADP-and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study. *J Thromb Thrombolysis.* 2024 Feb 12. doi: 10.1007/s11239-023-02937-0 (JCR 2022: IF 5.2)

3. Hesselbarth D, Gjermani D, Szabo S, Siegel PM, Diehl P, Moser M, Bode C, **Olivier CB**. Time from blood draw to multiple electrode aggregometry and association with platelet reactivity. *J Thromb Thrombolysis*. 2022 Nov 8. doi: 10.1007/s11239-022-02720-7 (JCR 2022: IF 5.2)
4. Gjermani D, Vetter H, Szabó S, Anfang V, Leggewie S, Hesselbarth D, Duerschmied D, Trenk D, **Olivier CB**. Thrombelastography Compared with Multiple Impedance Aggregometry to Assess High On-Clopidogrel Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. *J Clin Med*. 2022 Jul 21;11(14):4237. doi: 10.3390/jcm11144237. (JCR 2022: IF 5.0)
5. Heger LA, Danzer M, Bode C, Hortmann M, Duerschmied D, **Olivier CB*** and Moser M*; *equally contributed Dual-pathway antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention in stable coronary artery disease: A single-centre, single operator, retrospective cohort study. *Front Med (Lausanne)*. 2020 Sep 30;7:414. (JCR 2020: IF 3.1)
6. Rilinger J, Meyer M, Schnabel K, Weik P, Charlet A, Esser J, Zhou Q, Bode C, Moser M, Diehl P, **Olivier CB**. High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. *J Thromb Thrombolysis*. 2016 Nov;42(4):558-65. (JCR 2023: IF 2.3)

Original, co-authored

1. Rahimi F, Löffelhardt N, Minners J, Breitbart P, Franke K, Hartikainen TS, Valina C, Mühlen CVZ, Nührenberg T, Kastrati A, Woitek F, Elsaesser A, Abdel-Wahab M, Sossalla S, Hochholzer W, Westermann D, Neumann FJ, Olivier C, Ferenc M. Randomised Comparison of Culotte- versus Double Kissing Crush Stenting in de novo non-left Main Coronary Bifurcation Lesions: Rationale and Design of the Bifurcation Bad Krozingen trial-3 (BBK-3). *J Cardiovasc Transl Res*. 2025 May 27. doi: 10.1007/s12265-025-10626-x. Epub ahead of print. PMID: 40425928. (JCR 2023: IF 2.4)
2. Feistritz HJ, Jobs A, Zeymer U, Schneider S, Lauten P, Ferenc M, Weferling M, Brinkmann R, Winkler S, Landmesser U, Trippel T, Stellbrink C, Wienbergen H, Fürnau G, Möllmann H, Linke A, Jung C, Lauten A, Achenbach S, Rassaf T, Schmitz T, Cremer S, **Olivier C**, Schächinger V, Sossalla S, Toischer K, Templin C, Sedding D, Clemmensen P, Tigges E, Meincke F, Sharar HA, Kulenthiran S, Schulze PC, Jacobshagen C, Frank D, Baldus S, Lehmann R, Spies C, Klein N, Eitel I, Zahn R, Schmeisser A, Gori T, Lurz P, Akin I, Chatzis G, Rizas K, Kessler T, Ademaj F, Elsässer A, Maier L, Öner A, Staudt A, Werner N, Geisler T, Keßler M, Ferrari MW, Seyfarth M, Nordbeck P, Ewen S, Bietau C, Haghighi A, Reinstadler SJ, Geppert A, Höslér N, Toth-Gayor G, Billmann B, Tschierschke R, Schmidt C, Fichtlscherer S, Thiele H; COMPLETE-NSTEMI Investigators. Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial: The COMPLETE-NSTEMI trial. *Am Heart J*. 2025 Apr 8: S0002-8703(25)00121-8. doi: 10.1016/j.ahj.2025.04.007. Epub ahead of print. PMID: 40209841 (JCR 2023: IF 3.7)
3. Muataz Ali Hamad, Krystin Krauel, Nancy Schanze, Mark Zurek, **Christoph B. Olivier**, Peter Kohl, Thomas G. Nührenberg & Daniel Duerschmied (2025) A multi-color flow cytometric method for characterizing murine reticulated platelets using SYTO 13, *Platelets*, 36:1, 2489020, DOI: 10.1080/09537104.2025.2489020 (JRC 2023: IF 3.7)
4. Kaur G, Huber JP, Zhang S, Stallmann D, Juelch C, **Olivier CB**, Duerschmied, Bettinger D, Krauel K. Plasma Factors might interfere with platelet function in patients with decompensated liver cirrhosis. *Thieme Hämostaseologie*. 2025, doi: 10.1055/s-0044-1801682 (JCR 2023: IF 2.6)

5. Motovska Z, Hlinomaz O, Mrozek J, Kala P, Geisler T, Hromadka M, Akin I, Precek J, Kettner J, Cervinka P, Montalescot G, Jarkovsky J, Belohlavek J, Bis J, Matejka J, Vodzinska A, Muzafarova T, Tomasov P, Schee A, Bartus S, Andrasova A, **Olivier CB**, Kovarik A, Ostadal P, Demlova R, Souckova L, Vulev I, Coufal Z, Kochman J, Marinov I, Kubica J, Ducrocq G, Karpisek M, Klimsa Z, Hudec M, Widimsky P, Bhatt DL, Group DS. Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. *EuroIntervention*. 2024 Oct 21;20(20):e1309-e1318. doi: 10.4244/EIJ-D-24-00203. PMID: 39432252; PMCID: PMC11472137 (JCR 2023: IF 7.8)
6. Taylor KA, Carroll MK, Short SA, Celestin BE, Gilbertson A, **Olivier CB**, Haddad F, Cauwenberghs N. Factors associated with lower quarter performance-based balance and strength tests: a cross-sectional analysis from the project baseline health study. *Front Sports Act Living*. 2024 Jul 15;6:1393332. doi: 10.3389/fspor.2024.1393332. PMID: 39081837; PMCID: PMC11287662. (JCR 2023: IF 2.3)
7. Taylor, K. A., Carroll, M., Short, S. A., Celestin, B. E., Gilbertson, A., **Olivier, C.**, Haddad, F., & Cauwenberghs, N. (2023). Identifying Factors Associated with Lower Quarter Performance-Based Balance and Strength Tests: the Project Baseline Health Study. *medRxiv*, 2023-08.
8. Zeymer U, Lober C, Richter S, **Olivier CB**, Huber K, Haring B, Schwimmbeck P, Andrassy M, Akin I, Cuneo A, Desch S, Thiele H, Geisler T. Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and/or with cardiogenic shock. *Eur Heart J Acute Cardiovasc Care*. 2023 Jul 7;12(7):462-463. doi: 10.1093/ehjacc/zuad041. PMID: 37042356. (JCR 2022: IF 4.1)
9. März W, Schmidt N, An Haack I, Dressel A, Grammer TB, Kleber ME, Baessler A, Beil FU, Gouni-Berthold I, Julius U, Kassner U, Katzmann JL, Klose G, König C, Koenig W, Koschker AC, Laufs U, Merkel M, Otte B, Parhofer KG, Hengstenberg W, Schunkert H, Stach-Jablonski K, Steinhagen-Thiessen E, **Olivier CB**, Hahmann H, Krzossok S, Vogt A, Müller-Wieland D, Schatz U. The German CaRe high registry for familial hypercholesterolemia - Sex differences, treatment strategies, and target value attainment. *Atheroscler Plus*. 2023 Jun 12;53:6-15. doi: 10.1016/j.athplu.2023.06.001. PMID: 37434912; PMCID: PMC10331285. (JCR 2022: IF 1.6)
10. Gjermeni D, Saglam NP, **Olivier CB**, Kühlkamp V. Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation. *Eur Heart J Open*. 2023 Jun 20;3(4):oead065. doi: 10.1093/ehjopen/oead065. PMID: 37427356; PMCID: PMC10329261. (JCR 2023: IF 38.1)
11. Piepenburg SM, Kaier K, **Olivier CB**, Bothe W, Heidt T, Jäckel M, et al.. Use and Outcomes of Acute Treatment Strategies in Patients with Severe Aortic Valve Stenosis. *Global Heart*. 2021;16(1):91. DOI: <http://doi.org/10.5334/gh.1055>; (JCR 2022: IF 3.4)
12. Siegel PM, Chalupsky J, **Olivier CB**, Bojti I, Pooth JS, Trummer G, Bode C, Diehl P. Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality. *J Thromb Thrombolysis*. 2021 Sep 16:1-10. doi: 10.1007/s11239-021-02562-9; (JCR 2022: IF 5.2)
13. Siegel PM, Sander L, Fricke A, Stamm J, Wang X, Sharma P, Bassler N, Ying YL, **Olivier CB**, Eisenhardt SU, Bode C, Ahrens I, Diehl P, Peter KH. P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells. *Scientific Reports. Sci Rep* **11**, 17459 (2021); (JCR 2022: IF 5.0)
14. Jank M, von Niessen N, **Olivier CB**, Schmitt H, Anto-Michel N, Hilgendorf I, Bode C, Moser M, Esser JS, Zhou Q Platelet Bone Morphogenetic Protein-4 Mediates Vascular Inflammation and Neointima Formation after Arterial Injury. *Cells*. 2021 Aug 8;10(8):2027. (JCR 2022: IF 7.7)

15. Heger LA, Glück T, Kaier K, Hortmann M, Rieder M, Siegel PM, Diehl P, Wengenmayer T, **Olivier CB**, Bode C, Busch HJ, Duerschmied D, Ahrens I. Medical History of Coronary Artery Disease and Time to Electrocardiogram in the Emergency Department: A Real-Life, Single-Center, Retrospective Analysis. *BMC Cardiovasc Disord*. 2021 Oct 7;21(1):480; (JCR 2021: IF 2.1)
16. Rieder M, Laumann R, Witsch T, Schanze N, Heger L, **Olivier CB**, Muehlen C, Bode C, Ahrens I, Lothar A, Duerschmied D, Hortmann M. Evaluation of serum serotonin as a biomarker for myocardial infarction and ischemia/reperfusion injury. *Appl. Sci*. 2020, 10(18), 6379 (JCR 2020: IF 2.8)
17. Leef GC, Perino AC, Askari M, Fan J, Ho PM, **Olivier CB**, Longo L, Mahaffey KW, Turakhia MP. Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration. *J Pharm Pract*. 2020 Oct;33(5):647-653. (JCR 2021: IF 1.3)
18. Yong CM, Sundaram V, Abnoui F, **Olivier CB**, Yang J, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Deliargyris E, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW. The Efficacy and Safety of Cangrelor in Single Vessel versus Multi Vessel Percutaneous Coronary Intervention: Insights from CHAMPION PHOENIX. *Clin Cardiol*. 2019 Jun 29;42(9):797-805 (JCR 2018: IF 2.5)
19. Rilinger J, Heilmann C, Beitingger U, **Olivier CB**, Diehl P, Beyersdorf F, Siepe M. Moderate ischemic mitral regurgitation. Coronary artery bypass grafting with versus without simultaneous treatment of the mitral valve is associated with comparable long-term survival. *J Cardiovasc Surg (Torino)*. 2018 Dec;59(6):830-835 (JCR 2016: IF 2.2)
20. Zhou Q, Einert M, Schmitt H, Wang Z, Pankratz F, **Olivier CB**, Bode C, Liao JK, Moser M. MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation. *Vascul Pharmacol*. 2016 Sep;84:67-73. (JCR 2014: IF 3.6)
21. Diehl P, Halscheid C, **Olivier C**, Helbing T, Bode C, Moser M. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. *Clin Res Cardiol*. 2011 Sep;100(9):765-71. (JCR 2010: IF 3.5)
22. Diehl P, **Olivier C**, Halscheid C, Helbing T, Bode C, Moser M. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. *Basic Res Cardiol*. 2010 May;105(3):379-87. (JCR 2009: IF 6.0)

Consensus Documents or Guidelines

1. Hochholzer W, Nührenberg T, Flierl U, **Olivier CB**, Landmesser U, Möllmann H, Dörr M, Mehilli J, Schäfer A, Dürschmied D, Sibbing D, El-Armouche A, Zeymer U, Neumann FJ, Ahrens I, Geisler T. Antithrombotische Therapie nach strukturellen kardialen Interventionen. *Kardiologe* 15, 57–70 (2021) (JCR 2021: IF 0.3)

Reviews (invited)

2. Gauchel N, Naber KG; **Olivier CB**, Staudacher D. Lokale Lyse der Lungenarterienembolie – eine ÜbersichtIntensiv- und Notfallbehandlung; Intensiv- und Notfallbehandlung, 10.5414/IBX0571 (JCR 2022: IF N/P)
3. Hesselbarth D, Nührenberg T, Hochholzer W, Gjermeni D, Dürschmied D, **Olivier CB**, Antithrombotika nach Interventionen struktureller Herzerkrankungen. *Arzneimitteltherapie* 2021;39:229-37 (IF N/P)
4. **Olivier CB**, Duerschmied D, Bode C. Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen Update 2019. *Der Klinikarzt* 2020; 49(03): 57-61 (IF N/P)

5. **Olivier CB**, Turakhia MP, Mahaffey KW. Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. *Expert Opin Drug Saf.* 2018 Mar;17(3):251-258. (JCR 2016: IF 3.5)
6. **Olivier CB**, Bode C, Moser M. Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention/Acute Coronary Syndrome. *Aktuel Kardiol* 2017; 6(05): 367-372 (IF N/P)
7. **Olivier CB**, Bode C, Moser M. Peri- und postinterventionelle Thrombozyten-Aggregationshemmung bei Diabetikern. *Vasomed* 2015; 5: 253-254. (IF N/K)
8. **Olivier CB**, Bode C, Moser M. Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration. *Herz.* 2014 Nov;39(7):808-13. (JCR 2013: IF 0.9)
9. Helbing T, **Olivier C**, Bode C, Moser M, Diehl P. Role of microparticles in endothelial dysfunction and arterial hypertension. *World J Cardiol.* 2014 Nov 26;6(11):1135-1139. Review (IF N/K)
10. Moser M, **Olivier CB**, Bode C. Triple antithrombotic therapy in cardiac patients: more questions than answers. *Eur Heart J.* 2014 Jan;35(4):216-23. (JCR 2012: IF 14.1)
11. Hentschel D, **Olivier CB**, Bode C, Diehl P. The Role of Procalcitonin in Septic Patients—A Brief Overview. *Transl Med* 4 (144), 2161-1025.1000144 (JRC 2023: IF 6.1)
12. **Olivier C**, Diehl P, Bode C, Moser M. Thrombin Receptor Antagonism in Antiplatelet Therapy. *Cardiol Ther* (2013) 2:57–68 (IF N/P)

Editorials, Comments, and Others (invited)

1. Zeymer U, **Olivier CB**, Duerschmied D. Aspirin in Dual Antiplatelet Therapy After PCI: One Duration Does Not Fit All. *Circulation: Cardiovascular Interventions.* 2025 Jul. (JCR 2023: IF 35.6)
2. Bode C, **Olivier CB**, Duerschmied D. Is Bleeding Always Bad?: Bad Boy Bleeding. *J Am Coll Cardiol.* 2019 Sep 24;74(12):1529-1531. (JCR 2018: IF 18.6)
3. Bode C, **Olivier CB**, Duerschmied D. Anticoagulation and anaemia: old opponents from the era of VKA? *Eur Heart J.* 2019 Aug 31. (JCR 2018: IF 23.2)
4. Diehl P, **Olivier C**, Bode C, Moser M. Editorial comment: Reduction of oxidative stress: a new indication for acetylsalicylic acid in coronary artery bypass surgery. *Eur J Cardiothorac Surg.* 2013 Jun;43(6):1163-4. (JCR 2023: IF 3.3)

Listed as investigator

1. **European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration** (EAS FHSC). Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study. *Lancet Diabetes Endocrinol.* 2024 Nov; 12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3. Epub 2024 Oct 4. PMID: 39374602. (JCR 2022: IF 98.4)
2. Fumagalli RM, Voci D, Bickdeli B, Bingisser R, Colucci G, Forgo G, Gerardi T, Gerber B, Grigorean A, Klok FA, Righini M, Robert-Ebadi H, Stortecky S, Ulrich S, Wolf S, Wyss D, Hobohm L, Kucher N, Barco S; **OVID investigators**. Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial. *Res Pract Thromb Haemost.* 2024 Jul 26;8(5):102534. doi: 10.1016/j.rpth.2024.102534. PMID: 39252826; PMCID: PMC11381852. (JCR 2023: IF 3.4)
3. Barco S, Virdone S, Götschi A, Ageno W, Arcelus J. I., Bingisser R, Colucci G, Cools k F., Duerschmied D., Gibbs H., Fumagalli RM., Gerber B., Haas S., Himmelreich J., Hobbs R., Hobohm L., Jacobson B., Kayani

- G., Lopez RD., MacCallum P., Micieli E., Righini M., Robert-Ebadi H., Rocha AT., Rosemann T., Sawhney J., Schellong S., Sebastian T., Spirk D., Stortecky S., Turpie A., Voci D., Kucher N., Pieper K., Held U., Kakkar AK., & OVID and ETHIC Investigators. (2023). Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the **OVID** and **ETHIC** trials. *Thrombosis research*, 230, 27-32. (JCR 2023: IF 3.7)
4. Voci, D., Götschi, A., Held, U., Bingisser, R., Colucci, G., Duerschmied, D., Fumagalli, RM., Gerber B., Hasse B., Keller D., Konstantinides S., Mach F., Rampini SK., Righini M., Ebadi HR., Rosemann T., Roth-Zetsche S., Sebastian T., Simon N., Spirk D., Stortecky S., Vaisnora L., Kucher N., & Barco, S. (2023). Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, **phase III OVID trial**. *Thrombosis research*, 221, 157-163. doi: 10.1016/j.thromres.2022.10.021. (JCR 2023: IF 3.7)
 5. Catapano, A. L., Tokgozoglu, L., Banach, M., Gazzotti, M., Olmastroni, E., Casula, M., Ray K.K., & **Lipid Clinics Network Group**. (2023). Evaluation of lipoprotein (a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network. *Atherosclerosis*, 370, 5-11. doi: 10.1016/j.atherosclerosis.2023.02.007; (JCR 2023: IF 4.9)
 6. Barco S, Voci D, Held U, Sebastian T, Bingisser R, Colucci G, Duerschmied D, Frenk A, Gerber B, Götschi A, Konstantinides SV, Mach F, Robert-Ebadi H, Rosemann T, Simon NR, Spechbach H, Spirk D, Stortecky S, Vaisnora L, Righini M, Kucher N; **OVID investigators**. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol*. 2022 Aug;9(8):e585-e593. doi: 10.1016/S2352-3026(22)00175-2. Epub 2022 Jun 30. (JCR 2022: IF 98.4)
 7. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; **PROMINENT Investigators**. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. *N Engl J Med*. 2022 Nov 24;387(21):1923-1934. Doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. (JCR 2023: 96.3)
 8. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The **SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial**. *Nat Med*. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. (JCR 2022: IF 82.9)
 9. Bauer A, Schreinlechner M, Sappeler N, Dolejsi T, Tilg H, Aulner BA, Weiss G, Bellmann-Weiler R, Adolf C, Wolf D, Pirklbauer M, Graziadei I, Gänzer H, von Bary C, May AE, Wöll E, von Scheidt W, Rassaf T, Duerschmied D, Brenner C, Käb S, Metzler B, Joannidis M, Kain HU, Kaiser N, Schwinger R, Witzembichler B, Alber H, Straube F, Hartmann N, Achenbach S, von Bergwelt-Baildon M, von Stülpnagel L, Schoenherr S, Forer L, Embacher-Aichhorn S, Mansmann U, Rizas KD, Massberg S; **ACEI-COVID investigators**. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. *Lancet Respir Med*. 2021 Aug;9(8):863-872. doi: 10.1016/S2213-2600(21)00214-9. Epub 2021 Jun 11. Erratum in: *Lancet Respir Med*. 2021 Aug 6; PMID: 34126053; PMCID: PMC8195495. (JCR 2023: IF 38.7)
 10. **Harenberg J**, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Verhamme P, Bauersachs R, Hetjens S, Weiss C; **Working Group Members**. Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.

Thromb Haemost. 2020 Jan;120(1):132-140. doi: 10.1055/s-0039-1700545. Epub 2019 Nov 8. (JCR 2023: IF 3.4)

11. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, Hung G, Lee J, Kowey P, Talati N, Nag D, Gummidipundi SE, Beatty A, Hills MT, Desai S, Granger CB, Desai M, Turakhia MP; **Apple Heart Study Investigators**. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. *N Engl J Med*. 2019 Nov 14;381(20):1909-1917. doi: 10.1056/NEJMoa1901183. PMID: 31722151; PMCID: PMC8112605. (JCR 2023: 96.3)

Publication list, by year

2025

1. Rahimi F, Löffelhardt N, Minners J, Breitbart P, Franke K, Hartikainen TS, Valina C, Mühlen CVZ, Nührenberg T, Kastrati A, Woitek F, Elsaesser A, Abdel-Wahab M, Sossalla S, Hochholzer W, Westermann D, Neumann FJ, **Olivier C**, Ferenc M. Randomised Comparison of Culotte- versus Double Kissing Crush Stenting in de novo non-left Main Coronary Bifurcation Lesions: Rationale and Design of the Bifurcation Bad Krozingen trial-3 (BBK-3). *J Cardiovasc Transl Res*. 2025 May 27. doi: 10.1007/s12265-025-10626-x. Epub ahead of print. PMID: 40425928. (JCR 2023: IF 2.4)
2. Feistritzer HJ, Jobs A, Zeymer U, Schneider S, Lauten P, Ferenc M, Weferling M, Brinkmann R, Winkler S, Landmesser U, Trippel T, Stellbrink C, Wienbergen H, Fürnau G, Möllmann H, Linke A, Jung C, Lauten A, Achenbach S, Rassaf T, Schmitz T, Cremer S, **Olivier C**, Schächinger V, Sossalla S, Toischer K, Templin C, Sedding D, Clemmensen P, Tigges E, Meincke F, Sharar HA, Kulenthiran S, Schulze PC, Jacobshagen C, Frank D, Baldus S, Lehmann R, Spies C, Klein N, Eitel I, Zahn R, Schmeisser A, Gori T, Lurz P, Akin I, Chatzis G, Rizas K, Kessler T, Ademaj F, Elsässer A, Maier L, Öner A, Staudt A, Werner N, Geisler T, Keßler M, Ferrari MW, Seyfarth M, Nordbeck P, Ewen S, Bietau C, Haghighi A, Reinstadler SJ, Geppert A, Hösler N, Toth-Gayor G, Billmann B, Tschierschke R, Schmidt C, Fichtlscherer S, Thiele H; COMPLETE-NSTEMI Investigators. Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial: The COMPLETE-NSTEMI trial. *Am Heart J*. 2025 Apr 8: S0002-8703(25)00121-8. doi: 10.1016/j.ahj.2025.04.007. Epub ahead of print. PMID: 40209841 (JCR 2023: IF 3.7)
3. Muataz Ali Hamad, Krystin Krauel, Nancy Schanze, Mark Zurek, **Christoph B. Olivier**, Peter Kohl, Thomas G. Nührenberg & Daniel Duerschmied (2025) A multi-color flow cytometric method for characterizing murine reticulated platelets using SYTO 13, *Platelets*, 36:1, 2489020, DOI: 10.1080/09537104.2025.2489020 (JRC 2023: IF 3.7)

2024

4. Motovska Z, Hlinomaz O, Mrozek J, Kala P, Geisler T, Hromadka M, Akin I, Precek J, Kettner J, Cervinka P, Montalescot G, Jarkovsky J, Belohlavek J, Bis J, Matejka J, Vodzinska A, Muzafarova T, Tomasov P, Schee A, Bartus S, Andrasova A, **Olivier CB**, Kovarik A, Ostadal P, Demlova R, Souckova L, Vulev I, Coufal Z, Kochman J, Marinov I, Kubica J, Ducrocq G, Karpisek M, Klimsa Z, Hudec M, Widimsky P, Bhatt DL, Group DS. Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. *EuroIntervention*. 2024 Oct 21;20(20):e1309-e1318. doi: 10.4244/EIJ-D-24-00203. PMID: 39432252; PMCID: PMC11472137 (JCR 2023: IF 7.8)
5. Taylor KA, Carroll MK, Short SA, Celestin BE, Gilbertson A, **Olivier CB**, Haddad F, Cauwenberghs N. Factors associated with lower quarter performance-based balance and strength tests: a cross-sectional analysis from the project baseline health study. *Front Sports Act Living*. 2024 Jul 15;6:1393332. doi: 10.3389/fspor.2024.1393332. PMID: 39081837; PMCID: PMC11287662. (JCR 2023: IF 2.3)
6. European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC). Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study. *Lancet Diabetes Endocrinol*. 2024 Nov;12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3. Epub 2024 Oct 4. PMID: 39374602. (JCR 2023: IF 44)
7. Fumagalli RM, Voci D, Bikdeli B, Bingisser R, Colucci G, Forgo G, Gerardi T, Gerber B, Grigorean A, Klok FA, Righini M, Robert-Ebadi H, Stortecky S, Ulrich S, Wolf S, Wyss D, Hobohm L, Kucher N, Barco S; **OVID investigators**. Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial. *Res Pract Thromb Haemost*. 2024 Jul 26;8(5):102534. doi: 10.1016/j.rpth.2024.102534. PMID: 39252826; PMCID: PMC11381852. (JCR 2023: IF 3.4)
8. Gjermani, D., Anfang, V., Szabó, S., Vetter, H., Venhoff, A. C., Leggewie, S., Hesselbarth, D., Trenk, D., Buechsel, M., Westermann, D., & **Olivier, C. B.** (2024). D-dimer and fibrinogen indicate ischemic risk in patients with atrial fibrillation after percutaneous coronary intervention. *Thrombosis Journal*, 22(1), 42. doi: <https://doi.org/10.1186/s12959-024-00610-x>. (JCR 2023: IF 2.6)
9. **Olivier CB**, Struß L, Suennen N, Kaier K, Heger L, Westermann D, Meerpohl JJ., Mahaffey KW. Accuracy of Event Rate and Effect Size Estimation in Major Cardiovascular Trials: A Systematic Review. (2024). Accuracy of Event Rate and Effect Size Estimation in Major Cardiovascular Trials: A Systematic Review. *JAMA Network Open*, 7(4), e248818-e248818. doi: 10.1001/jamanetworkopen.2024.8818. (JCR 2023: IF 10.5)
10. Gjermani D., Anfang V., Vetter H., Szabó S., Hesselbarth D., Gauchel N., Siegel PM., Kaier K., Kille A., Franke A., Leggewie S., Trenk D., Duerschmied D., Bode C., Westermann D., & **Olivier CB.** (2024). Low on-clopidogrel ADP-and TRAP-6-induced platelet aggregation in patients with atrial fibrillation undergoing percutaneous coronary intervention: an observational pilot study. *J Thromb Thrombolysis*. 2024 Feb 12. doi: 10.1007/s11239-023-02937-0. (JCR 2023: IF 2.3)

2023

11. Taylor, K. A., Carroll, M., Short, S. A., Celestin, B. E., Gilbertson, A., **Olivier, C.**, Haddad ,F., & Cauwenberghs, N. (2023). Identifying Factors Associated with Lower Quarter Performance-Based Balance and Strength Tests: the Project Baseline Health Study. *medRxiv*, 2023-08.
12. Zeymer U, Lober C, Richter S, **Olivier CB**, Huber K, Haring B, Schwimbeck P, Andrassy M, Akin I, Cuneo A, Desch S, Thiele H, Geisler T. Cangrelor in patients with percutaneous coronary intervention for acute

- myocardial infarction after cardiac arrest and/or with cardiogenic shock. *Eur Heart J Acute Cardiovasc Care*. 2023 Jul 7;12(7):462-463. doi: 10.1093/ehjacc/zuad041. PMID: 37042356. (JCR 2022: 4.1)
13. März W, Schmidt N, An Haack I, Dressel A, Grammer TB, Kleber ME, Baessler A, Beil FU, Gouni-Berthold I, Julius U, Kassner U, Katzmann JL, Klose G, König C, Koenig W, Koschker AC, Laufs U, Merkel M, Otte B, Parhofer KG, Hengstenberg W, Schunkert H, Stach-Jablonski K, Steinhagen-Thiessen E, **Olivier CB**, Hahmann H, Krzossok S, Vogt A, Müller-Wieland D, Schatz U. The German CaRe high registry for familial hypercholesterolemia - Sex differences, treatment strategies, and target value attainment. *Atheroscler Plus*. 2023 Jun 12;53:6-15. doi: 10.1016/j.athplu.2023.06.001. PMID: 37434912; PMCID: PMC10331285. (JCR 2022: IF 1.6)
 14. Gjermani D, Saglam NP, **Olivier CB**, Kühlkamp V. Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation. *Eur Heart J Open*. 2023 Jun 20;3(4):oead065. doi: 10.1093/ehjopen/oead065. PMID: 37427356; PMCID: PMC10329261. (JCR 2023: IF 38.1)
 15. Barco, S., Virdone, S., Götschi, A., Ageno, W., Arcelus, J. I., Bingisser, R., Colucci, G., Cools k F., Duerschmied D., Gibbs H., Fumagalli RM., Gerber B., Haas S., Himmelreich J., Hobbs R., Hobohm L., Jacobson B., Kayani G., Lopez RD., MacCallum P., Micieli E., Righini M., Robert-Ebadi H., Rocha AT., Rosemann T., Sawhney J., Schellong S., Sebastian T., Spirk D., Stortecky S., Turpie A., Voci D., Kucher N., Pieper K., Held U., Kakkar AK., & **OVID and ETHIC Investigators**. (2023). Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the **OVID** and **ETHIC** trials. *Thrombosis research*, 230, 27-32. (JCR 2023: IF 3.7)
 16. Voci, D., Götschi, A., Held, U., Bingisser, R., Colucci, G., Duerschmied, D., Fumagalli, RM., Gerber B., Hasse B., Keller D., Konstantinides S., Mach F., Rampini SK., Righini M., Ebadi HR., Rosemann T., Roth-Zetzsche S., Sebastian T., Simon N., Spirk D., Stortecky S., Vaisnora L., Kucher N., & Barco, S. (2023). Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, **phase III OVID trial**. *Thrombosis research*, 221, 157-163. doi: 10.1016/j.thromres.2022.10.021 (JCR 2023: IF 3.7)
 17. Catapano, A. L., Tokgözoğlu, L., Banach, M., Gazzotti, M., Olmastroni, E., Casula, M., Ray K.K., & **Lipid Clinics Network Group**. (2023). Evaluation of lipoprotein (a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network. *Atherosclerosis*, 370, 5-11. doi: 10.1016/j.atherosclerosis.2023.02.007; (JCR 2023: IF 4.9)

2022

18. Hesselbarth D, Gjermani D, Szabo S, Siegel PM, Diehl P, Moser M, Bode C, **Olivier CB**. Time from blood draw to multiple electrode aggregometry and association with platelet reactivity. *J Thromb Thrombolysis*. 2022 Nov 8. doi: 10.1007/s11239-022-02720-7. (JCR 2023: IF 2.3)
19. Gauchel N, Naber KG; **Olivier CB**, Staudacher D. Lokale Lyse der Lungenarterienembolie – eine ÜbersichtIntensiv- und Notfallbehandlung; Intensiv- und Notfallbehandlung, 10.5414/IBX0571 (JCR 2022 IF N/P)
20. Barco S, Voci D, Held U, Sebastian T, Bingisser R, Colucci G, Duerschmied D, Frenk A, Gerber B, Götschi A, Konstantinides SV, Mach F, Robert-Ebadi H, Rosemann T, Simon NR, Spechbach H, Spirk D, Stortecky S, Vaisnora L, Righini M, Kucher N; **OVID investigators**. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet Haematol*. 2022 Aug;9(8):e585-e593. doi: 10.1016/S2352-3026(22)00175-2. Epub 2022 Jun 30. (JCR 2022: IF 98.4)

21. Gjermeni D, Vetter H, Szabó S, Anfang V, Leggewie S, Hesselbarth D, Duerschmied D, Trenk D, **Olivier CB**. Thrombelastography Compared with Multiple Impedance Aggregometry to Assess High On-Clopidogrel Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. *J Clin Med*. 2022 Jul 21;11(14):4237. doi: 10.3390/jcm11144237. (JCR 2023: IF 3.0)
22. Siegel PM, Chalupsky J, **Olivier CB**, Bojti I, Pooth JS, Trummer G, Bode C, Diehl P. Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality. *J Thromb Thrombolysis*. 2022 Apr;53(3):712-721. doi: 10.1007/s11239-021-02562-9. Epub 2021 Sep 16. (JCR 2023: IF 2.3)
23. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; **PROMINENT Investigators**. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. *N Engl J Med*. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. (JCR 2023: 96.3)
24. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The **SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial**. *Nat Med*. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. (JCR 2022: IF 82.9)

2021

25. Piepenburg SM, Kaier K, **Olivier CB**, Bothe W, Heidt T, Jäckel M, et al.. Use and Outcomes of Acute Treatment Strategies in Patients with Severe Aortic Valve Stenosis. *Global Heart*. 2021;16(1):91. DOI: <http://doi.org/10.5334/gh.1055> (JCR 2023: IF 3.0)
26. Hesselbarth D, Nührenberg T, Hochholzer W, Gjermeni D, Dürschmied D, **Olivier CB**. Antithrombotika nach Interventionen struktureller Herzerkrankungen. *Arzneimitteltherapie* 2021;39:229-37
27. Hochholzer W, Nührenberg T, Flierl U, **Olivier CB**, Landmesser U, Möllmann H, Dörr M, Mehilli J, Schäfer A, Dürschmied D, Sibbing D, El-Armouche A, Zeymer U, Neumann FJ, Ahrens I, Geisler T. Antithrombotische Therapie nach strukturellen kardialen Interventionen. *Kardiologie* 15, 57–70 (2021)
28. Siegel PM, Chalupsky J, **Olivier CB**, Bojti I, Pooth JS, Trummer G, Bode C, Diehl P. Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality. *J Thromb Thrombolysis*. 2022 Apr;53(3):712-721. doi: 10.1007/s11239-021-02562-9. Epub 2021 Sep 16. PMID: 34529213; PMCID: PMC8444511. (JCR 2023: IF 2.3)
29. Siegel PM, Sander L, Fricke A, Stamm J, Wang X, Sharma P, Bassler N, Ying YL, **Olivier CB**, Eisenhardt SU, Bode C, Ahrens I, Diehl P, Peter KH. P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells. *Scientific Reports. Sci Rep* **11**, 17459 (2021)
30. Jank M, von Niessen N, **Olivier CB**, Schmitt H, Anto-Michel N, Hilgendorf I, Bode C, Moser M, Esser JS, Zhou Q Platelet Bone Morphogenetic Protein-4 Mediates Vascular Inflammation and Neointima Formation after Arterial Injury. *Cells*. 2021 Aug 8;10(8):2027.

31. Heger LA, Glück T, Kaier K, Hortmann M, Rieder M, Siegel PM, Diehl P, Wengenmayer T, **Olivier CB**, Bode C, Busch HJ, Duerschmied D, Ahrens I. Medical History of Coronary Artery Disease and Time to Electrocardiogram in the Emergency Department: A Real-Life, Single-Center, Retrospective Analysis. *BMC Cardiovasc Disord*. 2021 Oct 7;21(1):480
32. **Olivier CB**, Middleton SK, Purington N, Shashidhar S, Hereford J, Mahaffey KW, Turakhia MP. Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation. *Cardiovascular Digital Health Journal* 2021;2:101–108
33. Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, Weiss G, Bellmann-Weiler R, Adolf C, Wolf D, Pirklbauer M, Graziadei I, Gänzer H, von Bary C, May AE, Wöll E, von Scheidt W, Rassaf T, Duerschmied D, Brenner C, Kääb S, Metzler B, Joannidis M, Kain HU, Kaiser N, Schwinger R, Witzenbichler B, Alber H, Straube F, Hartmann N, Achenbach S, von Bergwelt-Baildon M, von Stülpnagel L, Schoenherr S, Forer L, Embacher-Aichhorn S, Mansmann U, Rizas KD, Massberg S; **ACEI-COVID investigators**. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. *Lancet Respir Med*. 2021 Aug;9(8):863-872. doi: 10.1016/S2213-2600(21)00214-9. Epub 2021 Jun 11. Erratum in: *Lancet Respir Med*. 2021 Aug 6;; PMID: 34126053; PMCID: PMC8195495.

2020

34. Heger LA, Danzer M, Bode C, Hortmann M, Duerschmied D, **Olivier CB*** and Moser M*; *equally contributed. Dual-pathway antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention in stable coronary artery disease: A single-centre, single operator, retrospective cohort study. *Front Med (Lausanne)*. 2020 Sep 30;7:414. (JCR 2020: 3.1)
35. **Olivier CB**, Sundaram V, Chertow G, Shashidhar S, McDonnell K, Ding V, Desai M, Mahaffey KW, Mell M. A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. *J Vasc Access*. 2020 Jul;21(4):467-474.
36. Leef GC, Perino AC, Askari M, Fan J, Ho PM, **Olivier CB**, Longo L, Mahaffey KW, Turakhia MP. Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration. *J Pharm Pract*. 2020 Oct;33(5):647-653.
37. Rieder M, Laumann R, Witsch T, Schanze N, Heger L, **Olivier CB**, Muehlen C, Bode C, Ahrens I, Lothar A, Duerschmied D, Hortmann M. Evaluation of serum serotonin as a biomarker for myocardial infarction and ischemia/reperfusion injury. *Appl. Sci*. 2020, 10(18), 6379
38. **Olivier CB**, Duerschmied D, Bode C. Klinische Studien zur antithrombotischen Therapie kardiovaskulärer Erkrankungen Update 2019. *Der Klinikarzt* 2020; 49(03): 57-61
39. **Harenberg J**, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Verhamme P, Bauersachs R, Hetjens S, Weiss C; **Working Group Members**. Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial. *Thromb Haemost*. 2020 Jan;120(1):132-140. doi: 10.1055/s-0039-1700545. Epub 2019 Nov 8. (JCR 2023: IF 3.4)

2019

40. **Olivier CB**, Fan J, Askari M, Mahaffey KW, Heidenreich PA, Perino AC, Leef GC, Ho PM, Harrington RA, Turakhia MP. Site Variation and Outcomes for Antithrombotic Therapy in AF Patients after PCI: Findings from the Veterans Health Administration. *Circ Cardiovasc Interv*. 2019 Aug;12(8):e007604.

41. **Olivier CB**, Bhatt DL, Leonardi S, Stone GW, Gibson CM, Steg PG, Hamm CW, Wilson MD, Mangum S, Price MJ, Prats J, White HD, Lopes RD, Harrington RA, Mahaffey KW. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX. *Circ Cardiovasc Interv.* 2019 Jul;12(7):e007342.
42. **Olivier CB**, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW. Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. *JAMA Cardiol.* 2019 Jan 1;4(1):7-15.
43. Yong CM, Sundaram V, Abnoui F, **Olivier CB**, Yang J, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Deliargyris E, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW. The Efficacy and Safety of Cangrelor in Single Vessel versus Multi Vessel Percutaneous Coronary Intervention: Insights from CHAMPION PHOENIX. *Clin Cardiol.* 2019 Jun 29;42(9):797-805
44. Bode C, **Olivier CB**, Duerschmied D. Is Bleeding Always Bad?: Bad Boy Bleeding. *J Am Coll Cardiol.* 2019 Sep 24;74(12):1529-1531.
45. Bode C, **Olivier CB**, Duerschmied D. Anticoagulation and anaemia: old opponents from the era of VKA? *Eur Heart J.* 2019 Aug 31.
46. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, Hung G, Lee J, Kowey P, Talati N, Nag D, Gummidipundi SE, Beatty A, Hills MT, Desai S, Granger CB, Desai M, Turakhia MP; **Apple Heart Study Investigators**. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. *N Engl J Med.* 2019 Nov 14;381(20):1909-1917. doi: 10.1056/NEJMoa1901183. PMID: 31722151; PMCID: PMC8112605. (JCR 2023: 96.3)

2018

47. **Olivier CB**, Sundaram V, Bhatt DL, Leonardi S, Lopes RD, Ding VY, Yang L, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, White HD, Desai M, Lynch DR., Harrington RA, Mahaffey KW. Definitions of Peri-Procedural Myocardial Infarction and the Association with One-Year Mortality: Insights from CHAMPION Trials. *Int J Cardiol.* 2018 Nov 1;270:96-101
48. Rilinger J, Heilmann C, Beiting U, **Olivier CB**, Diehl P, Beyersdorf F, Siepe M. Moderate ischemic mitral regurgitation. Coronary artery bypass grafting with versus without simultaneous treatment of the mitral valve is associated with comparable long-term survival. *J Cardiovasc Surg (Torino).* 2018 Dec;59(6):830-835
49. **Olivier CB**, Turakhia MP, Mahaffey KW. Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. *Expert Opin Drug Saf.* 2018 Mar;17(3):251-258.

2017

50. **Olivier CB**, Bode C, Moser M. Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention/Acute Coronary Syndrome. *Aktuel Kardiolog* 2017; 6(05): 367-372

2016

51. Zhou Q, Einert M, Schmitt H, Wang Z, Pankratz F, **Olivier CB**, Bode C, Liao JK, Moser M. MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation.. *Vascul Pharmacol*. 2016 Sep;84:67-73.
52. Rilinger J, Meyer M, Schnabel K, Weik P, Charlet A, Esser J, Zhou Q, Bode C, Moser M, Diehl P, **Olivier CB**. High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. *J Thromb Thrombolysis*. 2016 Nov;42(4):558-65. (JCR 2023: IF 2.3)
53. **Olivier CB**, Weik P, Meyer M, Weber S, Diehl P, Bode C, Moser M, Zhou Q. Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors. *J Thromb Thrombolysis*. 2016 Aug;42(2):161-6. (JCR 2023: IF 2.3)
54. **Olivier CB**, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. *Thromb Res*. 2016 Feb;138:63-8.
55. **Olivier CB**, Schnabel K, Weber S, Zhou Q, Bode C, Moser M, Diehl P. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on bodyweight in contrast to clopidogrel. *J Thromb Thrombolysis*. 2016 Jul;42(1):84-9. (JCR 2023: IF 2.3)
56. **Olivier CB**, Meyer M, Bauer H, Schnabel K, Weik P, Zhou Q, Bode C, Moser M, Diehl P. The ratio of ADP- to TRAP-induced platelet aggregation quantifies P2Y12-dependent platelet inhibition independently of the platelet count. *PLoS One*. 2016 Feb 17;11(2):e0149053.

2015

57. **Olivier CB**, Bode C, Moser M. Peri- und postinterventionelle Thrombozyten-Aggregationshemmung bei Diabetikern. *Vasomed* 2015; 5: 253-254.

2014

58. Moser M, **Olivier CB**, Bode C. Triple antithrombotic therapy in cardiac patients: more questions than answers. *Eur Heart J*. 2014 Jan;35(4):216-23.
59. **Olivier CB**, Schnabel K, Brandt C, Weik P, Olschewski M, Zhou Q, Bode C, Diehl P, Moser M. A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone. *Clin Res Cardiol*. 2014 Dec;103(12):968-75.
60. **Olivier CB**, Diehl P, Schnabel K, Weik P, Zhou Q; Bode C, Moser M. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. *Thromb Haemost*. 2014 Feb;111(2):266-72. (JCR 2023: IF 3.4)
61. **Olivier CB**, Bode C, Moser M. Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration. *Herz*. 2014 Nov;39(7):808-13.
62. Helbing T, **Olivier C**, Bode C, Moser M, Diehl P. Role of microparticles in endothelial dysfunction and arterial hypertension. *World J Cardiol*. 2014 Nov 26;6(11):1135-1139.
63. Hentschel D, **Olivier CB**, Bode C, Diehl P. The Role of Procalcitonin in Septic Patients—A Brief Overview. *Transl Med* 4 (144), 2161-1025.1000144

2013

64. **Olivier C**, Diehl P, Bode C, Moser M. Thrombin Receptor Antagonism in Antiplatelet Therapy. *Cardiol Ther* (2013) 2:57–68
65. Diehl P, **Olivier C**, Bode C, Moser M. Editorial comment: Reduction of oxidative stress: a new indication for acetylsalicylic acid in coronary artery bypass surgery. *Eur J Cardiothorac Surg*. 2013 Jun;43(6):1163-4.

2011

66. Diehl P, Halscheid C, **Olivier C**, Helbing T, Bode C, Moser M. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. *Clin Res Cardiol*. 2011 Sep;100(9):765-71. (JCR 2010: IF 3.5)

2010

67. Diehl P, **Olivier C**, Halscheid C, Helbing T, Bode C, Moser M. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. *Basic Res Cardiol*. 2010 May;105(3):379-87.

A b s t r a c t s

2025

1. Kaur, G., Huber, JP., Zhang, S., Stallmann, D., Juelch, C., Olivier CB., Duerschmied, D., Bettinger, D., Krauel, K. Plasma Factors might interfere with platelet function in patients with decompensated liver cirrhosis. *Thieme Hämostaseologie*. 2025, doi: 10.1055/s-0044-1801682

2024

2. Oettinger, V., Von Zur Muelhen, C., Hilgendorf, I., Wolf, D., Rilinger, J., Gauchel, N., Maier, A., Wessinger, M., Kaier, K., Westermann, D. & Olivier, C. (2024). Recent secular trends of catheter-directed therapy for treatment of pulmonary embolism: a retrospective cohort study based on German national data. *European Heart Journal*, 45(Supplement_1), ehae666-2204

2023

3. Hesselbarth, D., D'orazio, M., Ciccarone, G., Gjermeni, D., Juelch, C., Rilinger, J., Breitbart P., Ruile P., Pottgiesser T., Von Zur Muehlen C., Duerschmied D., Westermann D., & Olivier, C. B. (2023). High rates of high on-aspirin platelet reactivity in patients after transcatheter aortic valve implantation. *European Heart Journal*, 44(Supplement_2), ehad655-2226.
4. Hesselbarth, D., D'orazio, M., Ciccarone, G., Gjermeni, D., Juelch, C., Rilinger, J., Pottgiesser T., Von Zur Muehlen C., Duerschmied D., Westermann D., & Olivier, C. B. (2023). Increased clot strength following transcatheter aortic valve replacement. *European Heart Journal*, 44(Supplement_2), ehad655-2227.

5. Gjermani, D., Szabo, S., Anfang, V., Vetter, H., Hesselbarth, D., Leggewie, S., Dietmar T., Duerschmied D., Westermann D., & Olivier, C. B. (2023). Association of Cytochrome P450 2C19 Polymorphism With Ischemic and Bleeding Risk in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. *Circulation*, 148(Suppl_1), A15688-A15688.
6. Bojti, I., Bojti, F., Hartikainen, T., Breitbart, P., Valina, C., Löffelhardt, N., Kaier K., Wolf D., Westermann D., & Olivier, C. B. (2023). Association of SGLT-2 Inhibition With Size of Myocardial Infarction in Patients With Type 2 Diabetes Mellitus. *Circulation*, 148(Suppl_1), A14605-A14605.

2022

7. Olivier, C. B., Struss, L., Suennen, N., Kaier, K., Heger, L. A., Meerpohl, J. J., & Mahaffey, K. W. (2022). Accuracy of event rate and effect size estimation in major cardiovascular trials. *European Heart Journal*, 43(Supplement_2), ehac544-2866.
8. Association of Cytochrome P450 2C19 polymorphisms with ischemic and bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention; Diona Gjermani, Sofia Szabo, Viktoria Anfang, Hannah Theresa Vetter, Carina Juelch, Stefan Leggewie, David Hesselbarth, Dietmar Trenk, Daniel Duerschmied, Christoph B Olivier. *Cardiovascular Research*, Volume 118, Issue Supplement_2, October 2022, cvac157.033, <https://doi.org/10.1093/cvr/cvac157.033>
9. Association of coagulation markers and antiphospholipid antibodies with ischemic and bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention; V Anfang, D Gjermani, S Szabo, H Vetter, D Hesselbarth, S Leggewie, C Bode, D Duerschmied, D Trenk, C B Olivier. *European Heart Journal*, Volume 43, Issue Supplement_2, October 2022, ehac544.1280, <https://doi.org/10.1093/eurheartj/ehac544.1280>
10. (best poster award public health) Genauigkeit der Effektgrößenschätzung in großen kardiovaskulären Studien. L. Struß, N. Sünnen, K. Kaier, E. Motschall, L. Heger, C. Bode1, K. Mahaffey, C. Olivier. *Clin Res Cardiol* (2022). <https://doi.org/10.1007/s00392-022-02002-5>

2021

11. Time from Blood Draw to Multiple Electrode Aggregometry and Association with On-Clopidogrel Platelet Reactivity; David Hesselbarth, Diona Gjermani, Sofia Szabo, Hannah Vetter, Viktoria Anfang, Philipp Diehl, Martin Moser, Christoph Bode, Christoph Olivier; *Circulation* 144 (Suppl_1), A11448-A11448
12. On-Clopidogrel Platelet Reactivity in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Association with Patient Characteristics; Diona Gjermani, Hannah Vetter, Sofia Szabo, Viktoria Anfang, David Hesselbarth, Stefan Leggewie, Dietmar Trenk, Daniel Duerschmied, Christoph Bode, Christoph Olivier. *Circulation* 144 (Suppl_1), A11338-A11338
13. Verschreibungspraktiken von Acetylsalicylsäure bei Patienten mit Vorhofflimmern nach koronarer Stent-Implantation: eine monozentrische Anwendungsbeobachtung. V. Anfang, D. Gjermani, S. Leggewie, H. Vetter, S. Szabò, C. Bode, D. Dürschmied, D. Trenk, C. Olivier. *Clin Res Cardiol* (2021) DOI <https://doi.org/10.1007/s00392-021-01843-w>

2020

14. Use and outcomes of emergency treatment strategies in patients with aortic valve stenosis. SM Piepenburg, K Kaier, C Olivier, M Zehender, C Bode, C Von Zur Muehlen, P Stachon. *European Heart*

Journal 41 (Supplement_2), ehaa946. 2598

15. Loss of platelet BMP4 reduces vascular inflammation and ameliorates vascular remodelling after carotid wire injury. Q Zhou, M Jank, N Von Niessen, CB Olivier, H Schmitt, N Anto-Michel, I Hilgendorf, C Bode, M Moser. European Heart Journal 41 (Supplement_2), ehaa946. 3787

2019

16. Why Digital Health Trials Can Fail: Lessons Learned from the SmartGUIDE Randomized Trial of Virtual Cardiac Rehabilitation; Christoph Olivier, Stephanie Middleton, Natasha Purington, Sumana Shashidhar, Kenneth W Mahaffey, Mintu Turakhia. Circulation: Cardiovascular Quality and Outcomes 12 (Suppl_1), A189-A189

2018

17. THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL. Christoph Olivier, Freddy Abnoui, Vandana Sundaram, Jaden Yang, Gregg Stone, Philippe Steg, C Michael Gibson, Christian Hamm, Matthew Price, Efthymios Deliargyris, Jayne Prats, Harvey White, Robert Harrington, Deepak Bhatt, Kenneth Mahaffey, Celina Yong, CHAMPION PHOENIX Investigators. Journal of the American College of Cardiology 71 (11S), A29-A29

2017

18. A Novel Class of Anti-inflammatory Binding Proteins Targeting $\alpha_M\beta_2$: *in vivo* Inhibition of Activated Monocytes in Intravital Microscopy. Xavier Tonnar, Patrick Siegel, Christoph Olivier, Thomas Helbing, Karlheinz Peter, Martin Moser, Christoph Bode, Philipp Diehl. Circulation 136 (suppl_1), A18419-A18419.
19. Site Variation and Trends for Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in the VA System: Findings From the TREAT-AF. Christoph B Olivier, Alexander C Perino, Jun Fan, Mariam Askari, George C Leef, Kenneth W Mahaffey, Mintu P Turakhia. Circulation 136 (suppl_1), A18194-A18194
20. TCT-339 Types of Myocardial Infarction in Patients with Peripheral Artery Disease: Insights From EUCLID Christoph Olivier, William Hiatt, Daniel Wojdyla, Schuyler Jones, Frank Rockhold, Jeffrey Berger, Brian Katona, Lars Norgren, Juuso Blomster, Manesh Patel. Journal of the American College of Cardiology 70 (18S), B139-B139
21. ONE-YEAR MORTALITY INCREASED IN PATIENTS WITH PERI-PROCEDURAL MYOCARDIAL INFARCTION: INSIGHTS FROM THE CHAMPION TRIALS. Christoph Olivier, Vandana Sundaram, Victoria Ding, Lingyao Yang, Sergio Leonardi, Renato Lopes, Deepak Bhatt, Gregg Stone, Philippe Steg, C Michael Gibson, Christian Hamm, Matthew Price, Harvey White, Manisha Desai, Robert Harrington, Donald R Lynch, Kenneth Mahaffey, CHAMPION Investigators. Journal of the American College of Cardiology 69 (11S), 7-7

2015

22. Designed Ankyrin Repeat Proteins Against Activation Specific Binding Sites of The Leukocyte Integrin $\alpha_M\beta_2$: Novel Strategies in Vascular Inflammation. Philipp Diehl, Patrick Siegel, Jessica Holien, Nicole Bassler, Ulrike Flierl, Xavier Tonnar, Christoph Olivier, Nathaly Anto Michel, Dennis Wolf, Andreas Zirlik,

Christoph B. Olivier

Daniel Steiner, Christoph Bode, Martin Moser, Michael Parker, Karlheinz Peter. Arteriosclerosis, Thrombosis, and Vascular Biology 35 (suppl_1), A413-A413

2012

23. Third generation P2Y₁₂ antagonists inhibit platelet aggregation more effectively than clopidogrel in a real world myocardial infarction registry. CB Olivier, C Brandt, Q Zhou, P Weik, P Diehl, C Bode, M Moser. EUROPEAN HEART JOURNAL 33, 322-322

2010

24. Discontinuation of longterm clopidogrel therapy is associated with rebound platelet hyperaggregability after 2 through 6 weeks. P Diehl, C Halscheid, C Olivier, T Helbing, C Bode, M Moser. EUROPEAN HEART JOURNAL 31, 174-174

2008

25. Clopidogrel Effect Depends on Body Weight and Abolishes Platelet Leukocyte Interaction in Patients with Coronary Artery Disease Treated by Stenting. P Diehl, C Olivier, C Halscheid, T Helbing, C Bode, M Moser. Circulation 118 (suppl_18), S_890-S_890

Invited Lectures and Reviewer Activities

Selected Invited Faculty Lectures

2022	DGK.Online: „Antithrombotische Therapie beim onkologischen Patienten“
2022	DGK.Online: „Individualisierte Therapie des Gefäßrisikopatienten? Fallbasierte Risikoeinschätzung und Behandlung in der Klinik“
2021	German Cardiac Society Herbsttagung „SARS-CoV-2 und thrombotische Komplikationen – was muss der Kliniker wissen?“
2021	Freiburg Bad Krozinger Herz-Kreislauf-Tage „Lokale Lyse“
2019	Freiburg Bad Krozinger Herz-Kreislauf-Tage „Digital Health und Arrhythmie-Management“
2019	German Cardiac Society AG19 “Antithrombotic Therapy in AF Patients after PCI”

Ad-hoc Reviewer Activities

Since 2021	Drugs - Real World Outcomes
Since 2020	Annals of Medicine
Since 2020	Scandinavian Cardiovascular Journal
Since 2019	Scientific Reports
Since 2019	Cochrane Heart
Since 2017	Thrombosis and Haemostasis

Christoph B. Olivier

Since 2017	Expert Review of Cardiovascular Therapy
Since 2017	American Heart Journal
Since 2016	Expert Opinion on Pharmacotherapy
Since 2016	Cardiovascular Therapeutics
Since 2016	Thrombosis Research
Since 2015	Platelets
Since 2012	PLOS ONE
Since 2011	Journal of Thrombosis and Thrombolysis
Since 2010	Journal of Thrombosis and Haemostasis

Professional Clinical Research Activities

Self-initiated clinical research studies

Since 2024	Heracles (principal investigator)
Since 2022	HemosPE (principal investigator)
Since 2022	HEMOSTAVR (principal investigator)
Since 2021	HPR AF PCI TEG (principal investigator)
Since 2020	HPR AF PCI pilot (principal investigator)
Since 2020	RISTRATAVI (principal investigator)
2014 – 2016	RETRAIN (principal investigator)
2013 – 2015	BIG-ROX-P (principal investigator)
2012 – 2014	MITAP (principal investigator)

Clinical Events Committee

Since 2020	SOS AMI (co-chair)
------------	--------------------

Data Safety Monitoring Board

2018	Apple Heart Study (safety desk)
2018 - 2021	PRONOUNCE (w/ Prof. Mahaffey)

Multi-center Clinical Trials: site investigator; selection

Since 2022	DAPT-SHOCK (principal investigator)
Since 2022	EPIDAURUS (principal investigator)
Since 2022	Hi-PEITHO (principal investigator)
Since 2022	Peitho-3 (principal investigator)
Since 2021	Clearance
Since 2022	STEP HFpEF DM (deputy)
Since 2021	OVID (investigator)
Since 2021	HERO (investigator)
Since 2021	CLEARANCE (investigator)
Since 2021	EMPACT-MI (deputy)
Since 2021	STEP HFpEF (deputy)
Since 2021	ENCOURAGE AF PCI (principal investigator)
Since 2020	DEDICATE DZHK
Since 2020	REBOOT
Since 2020	LeiKD
Since 2019	BIOSOLVE-IV
Since 2019	Reducer-I

Since 2019	Digit-HF
Since 2020	CaRe High (principal investigator)
Since 2020	ECLS Shock
Since 2019	AEGIS II (investigator)
Since 2019	REDUCE LAP II (investigator)
Since 2019	DIGIT HF (investigator)
2020 – 2021	EMPULSE (principal investigator)
2019 – 2021	PARADISE (deputy)
2019 – 2020	PEITHO II (investigator)
2019 – 2020	ACTIVITY (deputy)
2019 – 2020	DOASENSE
2019	EMPERIAL reduced (investigator)
2019	EMPERIAL preserved (investigator)
2014 – 2016	PIONEER AF PCI (deputy)
2010 – 2011	TRACER (investigator)
2010 – 2011	TRIGGER PCI (investigator)

Director of operations (site)

Since 2022	DEFINE-GPS
Since 2022	TAVI-PCI
Since 2022	DAPT-SHOCK (principal investigator)
Since 2022	EPIDAURUS (principal investigator)
Since 2022	Hi-PEITHO (principal investigator)
Since 2022	Peitho-3 (principal investigator)
Since 2022	CMR-ICD
Since 2021	Proof
Since 2021	Clearance
Since 2022	STEP HFpEF DM (deputy)
Since 2021	OVID (investigator)
Since 2021	HERO (investigator)
Since 2021	CLEARANCE (investigator)
Since 2021	EMPACT-MI (deputy)
Since 2020	DEDICATE DZHK
Since 2020	REBOOT
Since 2021	Apollo
Since 2020	LeiKD
Since 2019	BIOSOLVE-IV
Since 2019	Reducer-I
Since 2019	Digit-HF

Christoph B. Olivier

Since 2021	STEP HFpEF (deputy)
Since 2021	ENCOURAGE AF PCI (principal investigator)
Since 2020	CaRe High (principal investigator)
Since 2020	ECLS Shock
Since 2019	AEGIS II (investigator)
Since 2019	REDUCE LAP II (investigator)
Since 2019	DIGIT HF (investigator)
2020 – 2021	EMPULSE (principal investigator)
2019 – 2021	PARADISE (deputy)
2019 – 2020	PEITHO II (investigator)
2019 – 2020	ACTIVITY (deputy)
2019 – 2020	DOASENSE
2019	CAPRI
2019 - 2020	EMPERIAL reduced (investigator)
2019- 2020	EMPERIAL preserved (investigator)

Professional Activities

Memberships

ESC Working group of Thrombosis **Nucleus member 2024-2028**

Nucleus member since 2019, AG19 “Kardiovaskuläre Hämostase und antithrombotische Therapie” of the German Cardiac Society (Deutsche Gesellschaft für Kardiologie); **2025-2027: chair**

ESC Working group of Thrombosis **Nucleus member 2024-2028**

Nucleus member since 2019, AG19 “Kardiovaskuläre Hämostase und antithrombotische Therapie” of the German Cardiac Society (Deutsche Gesellschaft für Kardiologie); **2023-2025: co-chair**

Gesellschaft für Thrombose und Hämostaseforschung

American College of Cardiology

European Society of Cardiology

German Cardiac Society

American Heart Association

University Heart Center Freiburg Bad Krozingen

Since 11/2021 Data protection officer, Department of Cardiology and Angiology
Heart Center Freiburg University

Since 01/2020 Internal Training Program, Department of Cardiology and Angiology I
Heart Center Freiburg University

Christoph B. Olivier

Since 02/2019

Head of the Clinical Trials Unit, Department of Cardiology and Angiology I
Heart Center Freiburg University

2019 – 2020

Chief fellow, Department of Cardiology and Angiology I
Heart Center Freiburg University

Teaching (cumulative 846 academic hours)

Seminars (600 academic hours)

Summer 2025	Klinische Studien Kardiologie (45m x 16=12h)
Summer 2025	Interventionelle Kardiologie, bedside teaching im Herzkatheterlabor (3h x 16[weeks] =48h)
Winter 2024/2025	Clinical Research Seminar (2h x 16 [weeks] = 32h)
Winter 2024/2025	Antithrombotic Therapy (1,5h x 16 [weeks] = 24h)
Winter 2024/2025	Molecular Medicine „Clinical Research Seminar“ (2h)
Winter 2024/2025	International Master Biomedical Sciences; Clinical Trial Design, Translational Research (3h)
Winter 2024/2025	MSc Cardiology Research; Antithrombotic drugs I and II (3hs)
Winter 2023/24	Clinical Research Seminar (2h x 16 [weeks] = 32h)
Winter 2023/24	Antithrombotic Therapy (2h x 16 [weeks] = 32h)
Winter 2023/24	Molecular Medicine „Clinical Research Seminar“ (2h)
Winter 2023/24	International Master Biomedical Sciences; Clinical Trial Design, Translational Research (3h)
Winter 2023/24	MSc Cardiology Research; Antithrombotic drugs I and II (3hs)
Summer 2023	Clinical Research Seminar (2h x 14 [weeks] = 28h)
Summer 2023	Antithrombotic Therapy (2h x 14 [weeks] = 28h)
Winter 2022/23	Clinical Research Seminar (2h x 16 [weeks] = 32h)
Winter 2022/23	Antithrombotic Therapy (2h x 16 [weeks] = 32h)
Winter 2022/23	Molecular Medicine „Clinical Research Seminar“ (2h)
Winter 2022/23	International Master Biomedical Sciences; Clinical Trial Design, Translational Research (6h)
Winter 2022/23	Vessel Diseases (2h)
Summer 2022	Vessel Diseases (2h)
Summer 2022	Clinical Research Seminar (2h x 14 [weeks] = 28h)
Summer 2022	Antithrombotic Therapy (2h x 14 [weeks] = 28h)
Winter 2021/22	International Master Biomedical Sciences; Clinical Trial Design, Journal Club (4h)
Winter 2021/22	Vessel Diseases (2h)
Winter 2021/22	Molecular Medicine „Clinical Research Seminar“(2h)
Winter 2021/22	Clinical Research Seminar (2h x 16 [weeks] = 32h)
Winter 2021/22	Antithrombotic Therapy (2h x 16 [weeks] = 32h)
Summer 2021	Vessel Diseases (2h)
Summer 2021	Clinical Research Seminar (2h x 14 [weeks] = 28h)
Summer 2021	Antithrombotic Therapy (2h x 14 [weeks] = 28h)
Winter 2020/21	International Master Biomedical Sciences; Clinical Trial Design, Journal Club (4h)

Winter 2020/21	Vessel Diseases (2h)
Winter 2020/21	Molecular Medicine „Clinical Research Seminar“(2h)
Winter 2020/21	Clinical Research Seminar (2h x 16 [weeks] = 32h)
Winter 2020/21	Antithrombotic Therapy (2h x 16 [weeks] = 32h)
Summer 2020	Vessel Diseases (2h)
Summer 2020	Clinical Research Seminar (2h x 14 [weeks] = 28h)
Winter 2019/20	International Master Biomedical Sciences; Clinical Trial Design, Journal Club (4h)
Winter 2019/20	Vessel Diseases (2h)
Winter 2019/20	Molecular Medicine „Clinical Research Seminar“ (2h)
Winter 2019/20	Clinical Research Seminar (2h x 16 [weeks] = 32h)
Summer 2019	Vessel Diseases (2h)
Summer 2019	Clinical Research Seminar (2h x 14 [weeks] = 28h)
Summer 2017	Molecular Cardiology (2h)
Winter 2016/17	Molecular Cardiology (2h)
Summer 2016	Vessel Diseases (2h)
Summer 2016	Molecular Cardiology (2h)
Winter 2015/16	Vessel Diseases (2h)
Winter 2015/16	Molecular Cardiology (2h)
Summer 2015	Vessel Diseases (2h)
Summer 2015	Molecular Cardiology (2h)
Winter 2014/15	Vessel Diseases (2h)
Winter 2014/15	Molecular Cardiology (2h)
Winter 2014/15	Policlinic, Medicine (2h)
Winter 2014/15	Molecular Cardiology (2h)
Summer 2014	Molecular Cardiology (2h)
Winter 2013/14	Molecular Cardiology (2h)
Summer 2013	Molecular Cardiology (2h)
Winter 2012/13	Molecular Cardiology (2h)
Summer 2012	Molecular Cardiology (2h)
Winter 2011/12	Molecular Cardiology (2h)
Summer 2011	Molecular Cardiology (2h)

Main Lecture (4 academic hours)

Winter 2023/24	Antithrombotic Therapy (1h)
Winter 2022/23	Antithrombotic Therapy (1h)
Winter 2021/22	Antithrombotic Therapy – Coronary Artery Disease (1h)
Winter 2020/21	Myocardial Infarction – Time to Reboot (1h)

Courses (230 academic hours)

Winter 2023/24	Internal Medicine („Blockpraktikum“; 12h)
Summer 2023	Internal Medicine („Blockpraktikum“; 12h)
Winter 2022/23	Internal Medicine („Blockpraktikum“; 12h)
Summer 2022	Internal Medicine („Blockpraktikum“; 12h)
Winter 2021/22	Internal Medicine („Blockpraktikum“; 12h)
Summer 2021	Internal Medicine („Blockpraktikum“; 12h)
Winter 2020/21	Internal Medicine („Blockpraktikum“; 12h)
Summer 2020	Internal Medicine („Blockpraktikum“; 12h)
Winter 2019/20	Internal Medicine („Blockpraktikum“; 12h)
Summer 2019	Internal Medicine („Blockpraktikum“; 24h)
Summer 2018	Internal Medicine („Blockpraktikum“; 12h)
Summer 2016	Internal Medicine („Blockpraktikum“; 12h)
Winter 2015/16	Internal Medicine („Blockpraktikum“; 12h)
Summer 2015	Internal Medicine („Blockpraktikum“; 12h)
Winter 2014/15	Internal Medicine („Blockpraktikum“; 24h)
Summer 2014	Internal Medicine („Blockpraktikum“; 12h)
Winter 2011/12	Physical Examination (6h)
Summer 2011	Internal Medicine („Blockpraktikum“; 4h)
Summer 2011	Introduction to Clinical Medicine (4h)

Other teaching activities (12 academic hours)

Winter 2022/2023	Wahlfach (one student)
Summer 2020	MentoMed (6h)
Summer 2019	MentoMed (6h)

State examination for medical doctors

Winter 2023/24	4 candidates
Winter 2022/23	4 candidates
Summer 2021	4 candidates

Communication

Podcast

1. Cardiovascular Digital Health, Journal via soundcloud.com, Digital Health trials, <https://soundcloud.com/user-157217169/interview-dr-christoph-oliver-why-digital-health-trials-can-fail>

1. Event Rates, Effect Sizes Often Overestimated in Major CV Trials. TCTMD, Cardiovascular Research Foundation, <https://www.tctmd.com/news/event-rates-effect-sizes-often-overestimated-major-cv-trials>.
2. Schwerer Infekt? Dann sollten Sie die Blutverdünnung anpassen – die ESC gibt Orientierungshilfe für die Antithrombose-Therapie, The heart.org, Deutsch Medscape, August 2023, <https://deutsch.medscape.com/artikelansicht/4912810>
3. Antithrombotische Therapie beim onkologischen Patienten, Deutsche Gesellschaft für Kardiologie, December 2022, <https://www.kardiologie.org/kardiovaskulaere-gerinnungstherapie-im-grenzbereich-mit-benachba/23766960>
4. Individualisierte Therapie des Gefäßrisikopatienten, Fallbasierte Risikoeinschätzung und Behandlung in der Klinik, Deutsche Gesellschaft für Kardiologie, May 2022, <https://www.kardiologie.org/der-weg-des-kardiovaskulaeren-risikopatienten-von-der-klinik-in-/21391998>

Summary

Research: main areas

Personalized antithrombotic therapy
Clinical trial methodology
Digital health solutions

Publications

Cumulative	64
Original, first or last	19
Original, co	18
Consensus Documents	1
Reviews or Comments	15

Publication metrics (per google scholar, date signed)

Citations	879
H-index	16

Funding [≈€]

Cumulative	1M
DFG/BMBF	420k
Stiftung	200k
Faculty	100k
Industry	230k

Clinical Study Experience

Active since	2010
Number of studies	>200
Self-initiated studies	9
Safety board member	2
Endpoint committees	1 (co-chair)

Freiburg, 08MAY2025

Christoph B. Olivier